Market Overview

Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Share:
Related JAZZ
Jazz Pharma To Evaluate If Generic Xyrem's FDA Waiver Meets Required Legal Conditions
15 Biggest Mid-Day Gainers For Wednesday
Teva Pharma: Your Brief On The Big Earnings Report Coming In February (Seeking Alpha)

In a report published Monday, Bank of America initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $74 price objective.

Bank of America reported that, “We initiated coverage of Jazz with a Buy rating and $74 PO, which is based on a sum-of-the-parts DCF analysis and does not require multiple expansion. We like Jazz's focus on areas with strong growth potential and franchise durability, and we expect strong sales and EPS growth over the next several years driven by Xyrem and Erwinaze.”

Jazz Pharmaceuticals closed at $56.03 on Monday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Dec 2016Cantor FitzgeraldInitiates Coverage OnOverweight
Aug 2016Janney CapitalInitiates Coverage onNeutral
Aug 2016Deutsche BankMaintainsBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Related Articles (JAZZ)

View Comments and Join the Discussion!